Key Highlights

  • The company expects to start SOTERIA Phase 2 in the second half of 2026.
  • The FDA granted Fast Track Designation to PLX-200 for CLN2 on March 17.
  • A $10 million private placement closed on May 28.
  • Dr. Will Charlton was named Chief Medical Officer on September 1.

Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotech focused on rare paediatric lysosomal storage disorders, has a market capitalisation of about $99.7 million on 49.85 million shares. The company has said it expects to start its SOTERIA Phase 2 basket trial in the second half of 2026, so the clock is running.

Latest Company Context

Polaryx's pipeline centres on PLX-200, a repurposed oral small molecule, with preclinical candidates PLX-100, PLX-300 and PLX-400. The company has 11 employees and was founded in 2014. The FDA granted Fast Track Designation to PLX-200 for late-infantile neuronal ceroid lipofuscinosis (CLN2) on March 17, 2026, and to all four SOTERIA indications on April 21. A $10 million private placement closed May 28. On August 25 the company said it was advancing operational readiness and remained on track for a second-half 2026 start, and on September 1 it named Dr. Will Charlton Chief Medical Officer.

Key Business Drivers

Value depends almost wholly on clinical progress. Fast Track status may allow more frequent FDA interaction and rolling review but does not assure approval. With only a $10 million raise cited, funding for a Phase 2 programme is a central question, and further equity issuance could dilute holders.

What Investors Should Watch

Investors may watch for confirmation that the first patient is dosed in SOTERIA, regulatory or site-activation announcements, the Q3 2026 quarterly report (likely in November, date unconfirmed), cash runway disclosures and any financing. The new CMO's early priorities may also be informative.

Fast Track Designations Beside a Small Team and Funding Questions

Polaryx combines promising regulatory designations with a small team and funding questions. Starting SOTERIA in the second half of 2026 is the milestone the company has committed to.